DD201975A5 - Verfahren zur gewinnung eines neuen thrombininhibitor - Google Patents
Verfahren zur gewinnung eines neuen thrombininhibitor Download PDFInfo
- Publication number
- DD201975A5 DD201975A5 DD81233916A DD23391681A DD201975A5 DD 201975 A5 DD201975 A5 DD 201975A5 DD 81233916 A DD81233916 A DD 81233916A DD 23391681 A DD23391681 A DD 23391681A DD 201975 A5 DD201975 A5 DD 201975A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- heparin
- thrombin
- iii
- inhibitor
- dextran sulfate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002897 heparin Drugs 0.000 claims abstract description 22
- 229920000669 heparin Polymers 0.000 claims abstract description 22
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 11
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 11
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims abstract description 10
- 108090000631 Trypsin Proteins 0.000 claims abstract description 9
- 102000004142 Trypsin Human genes 0.000 claims abstract description 9
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 9
- 239000012588 trypsin Substances 0.000 claims abstract description 9
- 108010088842 Fibrinolysin Proteins 0.000 claims abstract description 7
- 229940012957 plasmin Drugs 0.000 claims abstract description 7
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 5
- 108090000935 Antithrombin III Proteins 0.000 claims abstract description 5
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 5
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 3
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 3
- 229960001322 trypsin Drugs 0.000 claims description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 abstract description 22
- 229960004072 thrombin Drugs 0.000 abstract description 20
- 108010074860 Factor Xa Proteins 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000004019 antithrombin Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 230000000937 inactivator Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229960002796 polystyrene sulfonate Drugs 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8128—Antithrombin III
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803038163 DE3038163A1 (de) | 1980-10-09 | 1980-10-09 | Thrombininhibitor, seine herstellung und verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD201975A5 true DD201975A5 (de) | 1983-08-24 |
Family
ID=6114000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD81233916A DD201975A5 (de) | 1980-10-09 | 1981-10-06 | Verfahren zur gewinnung eines neuen thrombininhibitor |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4379142A (fr) |
| EP (1) | EP0049861B1 (fr) |
| JP (1) | JPS5932443B2 (fr) |
| AT (1) | ATE13489T1 (fr) |
| DD (1) | DD201975A5 (fr) |
| DE (2) | DE3038163A1 (fr) |
| ES (1) | ES505829A0 (fr) |
| SU (1) | SU1271379A3 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689323A (en) * | 1983-09-26 | 1987-08-25 | Miles Laboratories, Inc. | Covalently bound heparin--antithrombin-III complex |
| FR2553518B1 (fr) * | 1983-10-13 | 1986-04-18 | Choay Sa | Nouveaux conjugues elabores par fixation d'un ligand sur un support insoluble, leur preparation et leurs applications biologiques |
| JPS60199819A (ja) * | 1984-03-23 | 1985-10-09 | Kowa Co | トロンビン結合性物質およびその製法 |
| NO164991C (no) * | 1984-09-21 | 1990-12-05 | Boehringer Ingelheim Int | Fremgangsmaate for fremstilling av blodkoaguleringshemmende proteiner. |
| FR2646775A1 (fr) * | 1989-05-11 | 1990-11-16 | Centre Nat Rech Scient | Utilisation du caseinoglycopeptide k, notamment de lait de vache, pour la fabrication d'une composition, notamment d'un medicament, pour la prevention et le traitement des thromboses |
| US5849703A (en) * | 1990-08-27 | 1998-12-15 | G. D. Searle & Co. | Pre-formed anticoagulant heparin/TFPI complexes |
| US6291427B1 (en) | 1990-08-27 | 2001-09-18 | G.D. Searle & Co. | Anticoagulant combination of LACI and sulfated polysaccharides |
| DE4203980A1 (de) * | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Verfahren zur bestimmung von hirudin und synthetischen thrombininhibitoren |
| US5476771A (en) * | 1993-02-22 | 1995-12-19 | The United States Of America As Represented By The Secretary Of The Army | Test for quantitative thrombin time |
| WO1993025220A1 (fr) * | 1992-06-05 | 1993-12-23 | Reid Thomas J Iii | Essai destine a la mesure quantitative du temps de formation de thrombine |
| AU6670198A (en) * | 1997-02-28 | 1998-09-18 | The Texas A & M University System | Heparan sulfate/heparin interacting protein compositions and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE392038B (sv) * | 1971-09-08 | 1977-03-14 | Kabi Ab | Forfarande for isolering av antitrombin ur blod eller blodprodukter |
| US4087415A (en) * | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
| JPS597693B2 (ja) * | 1978-01-07 | 1984-02-20 | 株式会社ミドリ十字 | 抗トロンビン製剤及びその製法 |
-
1980
- 1980-10-09 DE DE19803038163 patent/DE3038163A1/de not_active Withdrawn
-
1981
- 1981-09-28 ES ES505829A patent/ES505829A0/es active Granted
- 1981-10-06 DE DE8181108018T patent/DE3170739D1/de not_active Expired
- 1981-10-06 DD DD81233916A patent/DD201975A5/de not_active IP Right Cessation
- 1981-10-06 EP EP81108018A patent/EP0049861B1/fr not_active Expired
- 1981-10-06 AT AT81108018T patent/ATE13489T1/de active
- 1981-10-08 US US06/309,665 patent/US4379142A/en not_active Expired - Fee Related
- 1981-10-09 JP JP56160368A patent/JPS5932443B2/ja not_active Expired
-
1982
- 1982-06-08 SU SU823450446A patent/SU1271379A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| ES8205813A1 (es) | 1982-08-16 |
| SU1271379A3 (ru) | 1986-11-15 |
| DE3038163A1 (de) | 1982-05-06 |
| EP0049861A2 (fr) | 1982-04-21 |
| US4379142A (en) | 1983-04-05 |
| JPS5793915A (en) | 1982-06-11 |
| EP0049861B1 (fr) | 1985-05-29 |
| ES505829A0 (es) | 1982-08-16 |
| JPS5932443B2 (ja) | 1984-08-09 |
| ATE13489T1 (de) | 1985-06-15 |
| DE3170739D1 (en) | 1985-07-04 |
| EP0049861A3 (en) | 1983-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0181465B2 (fr) | Protéines inhibant la coagulation du sang, leur application | |
| DE3586402T3 (de) | Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung. | |
| DE2734821C3 (de) | Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung | |
| EP0888386B2 (fr) | Concentré d'un complèxe du facteur VIII, stable et sans virus | |
| EP0409053B1 (fr) | Procédé pour purifier les annexines | |
| EP1074616B1 (fr) | Procédé pour la purification du proenzmye de la protéase qui active le facteur VII, par chromatographie d'échange ionique | |
| EP0049877B1 (fr) | Procédé et réactif pour la détermination de l'antithrombine-BM | |
| EP0100985B1 (fr) | Inhibiteurs d'élastase, leur procédé de préparation et les médicaments les contenant | |
| DD201975A5 (de) | Verfahren zur gewinnung eines neuen thrombininhibitor | |
| EP0018353A1 (fr) | Procédé de préparation de fractions de plasma exemptes d'effets secondaires | |
| DE3043409C2 (fr) | ||
| DE69429868T2 (de) | Verfahren zur herstellung eines inter-alpha-trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat | |
| DE2734427C3 (de) | Verfahren zur Gewinnung von thrombinartigen Enzymen aus Schlangengiften | |
| EP0700684A2 (fr) | Composition contenant un concentré d'un complexe de la prothrombine et au minimum un composé supplémentaire qui active la coagulation, en tant qu'antidote des anticoagulants sanguins | |
| DE2532151C3 (de) | Antisenim zur quantitativen Bestimmung der Abbauprodukte des Fibrins und Fibrinogen« und Verfahren zu seiner Herstellung | |
| DE2711164A1 (de) | Antiplasmin und ein antiserum dagegen | |
| DE69433875T2 (de) | Verfahren zur präparation von humanem aktiviertem protein c | |
| DE3034045C2 (fr) | ||
| EP0048898B1 (fr) | Procédé de preparation d'un complexe antithrombine-héparine et compositions pharmaceutiques le contenant | |
| EP0255651B1 (fr) | Agent pour le traitement de l'hémophilie-A résistante au facteur VIII et son procédé de préparation | |
| EP0700682A2 (fr) | Médicaments contenant de la prothrombine pour antagoniser les anticoagulants sanguins | |
| DE2063070A1 (de) | Verfahren zur Isolierung eines fibrinstabilisierenden Faktors | |
| EP0332985B1 (fr) | Méthode de purification du facteur XII par chromatographie d'affinité | |
| DE3835815A1 (de) | Neue isohirudine | |
| DE2808396A1 (de) | Protease-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |